LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | CGP60474 | 10.0 | uM | LJP6 | 2 | G01 | 72 | hr | 1476 | 826 | 3694 | 0.2236 | -0.2935 |
| SK-BR-3 | CGP60474 | 10.0 | uM | LJP6 | 3 | G01 | 72 | hr | 1476 | 610 | 3694 | 0.1651 | -0.3909 |
| SK-BR-3 | CHIR-99021 | 10.0 | uM | LJP6 | 1 | P13 | 72 | hr | 1476 | 2425 | 3694 | 0.6565 | 0.4277 |
| SK-BR-3 | CHIR-99021 | 10.0 | uM | LJP6 | 2 | P13 | 72 | hr | 1476 | 2246 | 3694 | 0.6080 | 0.3469 |
| SK-BR-3 | CHIR-99021 | 10.0 | uM | LJP6 | 3 | P13 | 72 | hr | 1476 | 2066 | 3694 | 0.5593 | 0.2658 |
| SK-BR-3 | CP724714 | 10.0 | uM | LJP5 | 1 | A07 | 72 | hr | 1476 | 1237 | 3694 | 0.3349 | -0.1081 |
| SK-BR-3 | CP724714 | 10.0 | uM | LJP5 | 2 | A07 | 72 | hr | 1476 | 1321 | 3694 | 0.3576 | -0.0702 |
| SK-BR-3 | CP724714 | 10.0 | uM | LJP5 | 3 | A07 | 72 | hr | 1476 | 1334 | 3694 | 0.3611 | -0.0644 |
| SK-BR-3 | CP466722 | 10.0 | uM | LJP5 | 1 | I07 | 72 | hr | 1476 | 1904 | 3694 | 0.5154 | 0.1927 |
| SK-BR-3 | CP466722 | 10.0 | uM | LJP5 | 2 | I07 | 72 | hr | 1476 | 1888 | 3694 | 0.5111 | 0.1855 |
| SK-BR-3 | CP466722 | 10.0 | uM | LJP5 | 3 | I07 | 72 | hr | 1476 | 1863 | 3694 | 0.5043 | 0.1742 |
| SK-BR-3 | Crizotinib | 10.0 | uM | LJP5 | 1 | A19 | 72 | hr | 1476 | 1058 | 3694 | 0.2864 | -0.1888 |
| SK-BR-3 | Crizotinib | 10.0 | uM | LJP5 | 2 | A19 | 72 | hr | 1476 | 1091 | 3694 | 0.2953 | -0.1740 |
| SK-BR-3 | Crizotinib | 10.0 | uM | LJP5 | 3 | A19 | 72 | hr | 1476 | 1135 | 3694 | 0.3073 | -0.1541 |
| SK-BR-3 | Momelotinib | 10.0 | uM | LJP5 | 1 | P07 | 72 | hr | 1476 | 1538 | 3694 | 0.4164 | 0.0276 |
| SK-BR-3 | Momelotinib | 10.0 | uM | LJP5 | 2 | P07 | 72 | hr | 1476 | 1536 | 3694 | 0.4158 | 0.0267 |
| SK-BR-3 | Momelotinib | 10.0 | uM | LJP5 | 3 | P07 | 72 | hr | 1476 | 1513 | 3694 | 0.4096 | 0.0164 |
| SK-BR-3 | Dasatinib | 10.0 | uM | LJP5 | 1 | D01 | 72 | hr | 1476 | 1207 | 3694 | 0.3267 | -0.1216 |
| SK-BR-3 | Dasatinib | 10.0 | uM | LJP5 | 2 | D01 | 72 | hr | 1476 | 1279 | 3694 | 0.3462 | -0.0892 |
| SK-BR-3 | Dasatinib | 10.0 | uM | LJP5 | 3 | D01 | 72 | hr | 1476 | 1179 | 3694 | 0.3192 | -0.1343 |
| SK-BR-3 | Dasatinib | 10.0 | uM | LJP6 | 1 | I01 | 72 | hr | 1476 | 832 | 3694 | 0.2252 | -0.2908 |
| SK-BR-3 | Dasatinib | 10.0 | uM | LJP6 | 2 | I01 | 72 | hr | 1476 | 933 | 3694 | 0.2526 | -0.2452 |
| SK-BR-3 | Dasatinib | 10.0 | uM | LJP6 | 3 | I01 | 72 | hr | 1476 | 879 | 3694 | 0.2380 | -0.2696 |
| SK-BR-3 | Dovitinib | 10.0 | uM | LJP5 | 1 | E19 | 72 | hr | 1476 | 1831 | 3694 | 0.4957 | 0.1598 |
| SK-BR-3 | Dovitinib | 10.0 | uM | LJP5 | 2 | E19 | 72 | hr | 1476 | 1583 | 3694 | 0.4285 | 0.0479 |